Efficacy of Dichlorophenolindophenol (DCIP) as Screening Test for Hb E: Revisited

Area of Science:

• Hematology
• Public Health
• Genetics

Background:

• Hb E-beta thalassemia is a significant public health concern in West Bengal, India.
• A need exists for accessible, cost-effective screening methods for HbE at the community level.

Purpose of the Study:

• To evaluate the 2,3-dicyano-5-methylphenyl-3,4-phenyl dicarboxylate (DCIP) test as a screening tool for HbE beta thalassemia.
• To compare the DCIP test with Hemoglobin High-Performance Liquid Chromatography (HPLC) and DNA mutation analysis.

Main Methods:

• A study was conducted on 425 asymptomatic family members of diagnosed HbE beta thalassemia patients.
• Blood samples were analyzed using Hb, RBC indices, DCIP test, and HPLC, with DNA mutation analysis for discordant cases.

Main Results:

• The DCIP test demonstrated high sensitivity (96.39%), specificity (97.43%), positive predictive value (96.39%), and negative predictive value (97.43%).
• False positive and false negative rates were 2.56% and 4.6%, respectively.
• The DCIP test is user-friendly, requires minimal technical skill, and is cost-effective compared to HPLC.

Conclusions:

• The DCIP test is a reliable, sensitive, and specific screening method for HbE beta thalassemia.
• Its ease of use and low cost make it ideal for community-level screening in resource-limited settings.
• The DCIP test can significantly aid in managing HbE beta thalassemia in public health initiatives.